Fabien Maldonado
Last active: 2/1/2016

Temozolomide-associated organizing pneumonitis.

Maldonado F, Limper AH, Lim KG, Aubrey MC
Mayo Clin Proc. 2007 82 (6): 771-3

PMID: 17550757

Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.

MeSH Terms (9)

Aged, 80 and over Antineoplastic Agents, Alkylating Dacarbazine Glioblastoma Humans Male Pneumocystis carinii Pneumonia, Pneumocystis Temozolomide

Connections (1)

This publication is referenced by other Labnodes entities:

Links